Jun. 30 at 12:40 AM
$SLS $LLY $PFE $ABBV $BMY
Kelonia is still in Phase 1, so durability is the open question. So Why did Lilly pay
$7B for a cancer therapy with 18 treated patients? At ASCO, Kelonia reported 100% response.
Kelonia developed an in vivo CAR-T for multiple myeloma - and the ASCO update is genuinely strong: every patient responded, the first treated remains in deep remission past 10 months, and safety has held so far. Why Lilly paid
$7B. Today's standard CAR-T is ex vivo: harvest a patient's cells, engineer them in a lab, precondition with chemo, and reinfuse. It's very expensive, slow, and gated by manufacturing. In vivo CAR-T is off-the-shelf - a one-time injection, no chemo prep, and a fraction of the cost.
Know what you own, GPS Regal Pivotal Registrational is a Phase 3 pre commercialization ready Platform for 20+ WT1 cancers with CURATIVE outcome, 0 Safety issues, 0 Toxicity, off the shelf not a complex Biologic=
$240.00+
